Kalinichev Mikhail sold (to issuer) 306,765 shares of ADXN
Kalinichev Mikhail (HEAD OF TRANSLATIONAL SCIENCE) sold (to issuer) 306,765 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh data on insider holdings, useful for short‑term traders.
Market read
Primary source filing; modest insider sell in a micro‑cap biotech.
What to watch
Potential tax or liquidity reasons for sale; no 10b5‑1 plan.
Background
SEC Form 4 filing reports insider transaction for Addex Therapeutics.
Ticker impact
Form 4 disclosed insider Mikhail Kalinichev sold 306,765 shares, leaving zero holdings.
Minor downward pressure, likely limited to short‑term volatility.
Head of Translational Science sold a sizable block; no 10b5‑1 plan, suggesting discretionary sale.
Market effects
Limited impact on biotech sector; typical insider sale.
No regional effect.
Low relevance globally.
Counterpoint
Sale could be unrelated to company outlook; may not indicate negative sentiment.
Key entities
- CompanyAddex Therapeutics Ltd.
Biotech firm listed on Nasdaq under ADXN.
- InsiderMikhail Kalinichev
Head of Translational Science at Addex.